Abstract 252P
Background
RCC accounts for nearly 4% of all malignancies, in the Philippines, RCC ranks as the 15th most common cancer in 2018. The National Kidney and Transplant institute Cancer registry ranks RCC as the institute’s 4th most common malignancy at 10%. Studies to improve the diagnostic work up and follow up of this rare malignancy but apparently common in this institution can contribute for a better management and characterization of RCC.
Methods
This is a retrospective cohort study which included all patients who underwent nephrectomy for localized renal cell cancer from January 2017 to December 2021.
Results
There were 464 eligible patients included in this study. Clinical factors associated with recurrence of RCC upon multivariate analysis are bilateral sidedness, pT2 and beyond, WHO Grade 3-4, tumor encompassing the entire kidney, sarcomatoid and rhabdoid features, tumor necrosis, tumor thrombus, lymphovascular space invasion and positive surgical margins. Most common sites of recurrence was lungs (58.33%) followed by lymph nodes (45.83%) then bones (20.83%).
Conclusions
Presence of poor prognostic factors as well as positive lymph nodes are highly associated with local and distant RCC recurrence. A more stringent follow up with appropriate imaging may allow early intervention of metastatic diseases and possible consideration of lymph node dissection may improve recurrence free survival.
Clinical trial identification
Editorial acknowledgement
101 Health research.
Legal entity responsible for the study
The author.
Funding
National Kidney and Transplant Institute.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract